News

Layla Capital's Second Fund Focuses on Real Estate Opportunities

Layla Capital's Second Fund Focuses on Real Estate Opportunities

Layla Capital Closes Initial Funding for Second Investment Fund

Layla Capital, a reputable direct commercial real estate lender, has successfully completed the initial closing of its second fund, known as Layla Fund II, LP. This exciting development highlights Layla's focus on investing in domestic debt opportunities up to $15 million, particularly in core real estate assets.

Commitments from High-Profile Investors

The initial round of commitments for Fund II has raised an impressive total of $50 million. This includes investments from ultra-high-net worth individuals, family offices, and various institutional clients. Layla's growing reputation in the lending landscape is attracting both new and existing investors to the Fund II.

Investment Strategy of Layla Fund II

With a clear mandate, Layla's Fund II is set to target senior secured real estate bridge loan opportunities. The firm is paying special attention to a variety of core assets. This encompasses single-family investment properties, multi-family complexes, mixed-use developments, retail spaces, industrial zones, warehousing options, and prime development sites. Layla's advanced lending platform has a proven track record with nearly 75 successfully closed deals since its inception in 2017. The average loan amounts to just over $4 million across its first two funds.

Commitment to High Standards

Justin Cooper, the founder and Managing Partner of Layla Capital, expresses gratitude towards current investors and welcomes new partners. He states, "In less than a decade, we have established Layla as a trustworthy name in private commercial real estate lending. Our commitment revolves around transparency, reliability, and consistent execution. With the ongoing fundraising for Fund II, we are excited to enhance our contributions to the marketplace and focus on delivering value to all stakeholders. This dedication has significantly influenced our success so far and spurred interest in our recent fund offerings."

Successful Track Record with Previous Fund

Layla Fund II follows the firm's successful inaugural fund, Layla Capital Fund I, which has closed over $54 million across 12 deals and diversified investments across various states and property types. This success demonstrates Layla's expertise in navigating the U.S. commercial real estate landscape, which is becoming increasingly intricate.

Addressing Market Needs

Max Deibel, a Partner at Layla Capital, points out that the commercial real estate market is complex, and capital solutions are often challenging to secure. He emphasizes, "Our firm focuses on filling this gap with significant market expertise and the latest technologies to streamline the lending process. Our diverse broker network allows us to uncover quality deals, providing us with valuable insights into the marketplace. The successful fundraising for Fund II showcases our effective approach, and I extend my thanks to our investors for their unwavering trust in us."

Looking Ahead with Promising Assets

As of June 1, 2025, Layla Capital manages nearly $100 million in assets, positioning the firm for continued growth and influence in the market. Their commitment to building strong client relationships and maintaining transparency is part of their core philosophy.

About Layla Capital

Founded in 2017, Layla Capital specializes in providing commercial real estate loans, offering amounts up to $15 million. The firm focuses on a wide range of asset types, including single-family and multi-family homes, mixed-use developments, retail, and industrial properties. Their dedication to swift and flexible lending solutions allows them to cater to the various needs of borrowers in search of reliable financial support.

Contact Information

For further inquiries, please reach out to Meaghan Tyrrell at Gaffney Bennett PR.

Frequently Asked Questions

What is the purpose of Layla Fund II?

Layla Fund II aims to invest in senior secured real estate bridge loan opportunities up to $15 million.

How much has Layla Capital raised for Fund II?

Layla Capital has secured $50 million in commitments from various investors for Fund II.

What types of assets does Layla focus on?

Layla focuses on core real estate assets, including residential, commercial, and mixed-use properties.

What is Layla Capital's track record?

Since its inception, Layla has successfully closed nearly 75 deals with an average loan size of over $4 million.

When was Layla Capital founded?

Layla Capital was founded in 2017 and has since established itself as a trusted name in commercial real estate lending.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 34

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 38

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 51

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 29

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 39

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 21

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 26

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering States to Value Workforce Credentials Effectively

Updated Category News Views 207

Initiating FutureReady States for Workforce Empowerment The FutureReady States initiative, spearheaded by the Lumina Foundation, is a transformative approach to evaluating workforce credential effectiveness. This program is designed to help states understand and enhance their investment in workforce training policies that yield significant economic benefits for both...

Continue Reading
Revolutionizing ADC Characterization with Biozen Native Columns

Updated Category News Views 467

Transforming Biotherapeutic Characterization First of its Kind in Biotherapeutic Antibody Characterization Phenomenex Inc., a leader in separation science technology, has launched Biozen Native RP-1 and RP-5 chromatography columns. These innovative products are engineered to meet the growing demand for effective characterization methods for Antibody-Drug Conjugates...

Continue Reading
Liberty HealthShare: A Compassionate Approach to Healthcare

Updated Category News Views 150

Liberty HealthShare: A Shift in Healthcare Sharing In recent years, many individuals have faced significant concerns about healthcare costs and insurance availability. Liberty HealthShare is stepping up to provide a compassionate alternative for those seeking an effective solution to diminishing healthcare options, especially amid rising premiums and decreasing coverage....

Continue Reading
SelectQuote, Inc. Announces Impressive Q2 Fiscal Results

Updated Category News Views 114

Record Quarter for SelectQuote, Inc. SelectQuote, Inc. (NYSE: SLQT) reported significant growth in its consolidated revenue for the second quarter of fiscal year 2025, reaching $481.1 million. This reflects a notable increase from $405.4 million in the same quarter of the prior year. Alongside revenue growth, the company achieved consolidated net income of $53.2 million,...

Continue Reading
Parker Hannifin to Reveal Fiscal 2025 Q2 Earnings Insights

Updated Category News Views 203

Parker Hannifin Corporation Upcoming Earnings Announcement Parker Hannifin Corporation (NYSE: PH), recognized as a global leader in motion and control technologies, has announced its plans to release its fiscal 2025 second quarter earnings. This exciting update is set to take place before the stock market opens on January 30, 2025. Investors and analysts eagerly...

Continue Reading